Zobrazeno 1 - 10
of 11 006
pro vyhledávání: '"Checkpoint blockade"'
Autor:
Jialiang Cai, Lina Song, Feng Zhang, Suiyi Wu, Guiqi Zhu, Peiling Zhang, Shiping Chen, Junxian Du, Biao Wang, Yufan Cai, Yi Yang, Jinglei Wan, Jian Zhou, Jia Fan, Zhi Dai
Publikováno v:
Cancer Communications, Vol 44, Iss 11, Pp 1231-1260 (2024)
Abstract Background The efficacy of immune checkpoint blockade therapy in patients with hepatocellular carcinoma (HCC) remains poor. Although serine‐ and arginine‐rich splicing factor (SRSF) family members play crucial roles in tumors, their impa
Externí odkaz:
https://doaj.org/article/43d701a4f6b24ef59b4dd2e4aed02f03
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-22 (2024)
Abstract Regulatory T cells (Tregs), an essential component of the human immune system, are a heterogeneous group of T lymphocytes with the ability to suppress immune responses and maintain immune homeostasis. Recent evidence indicates that Tregs may
Externí odkaz:
https://doaj.org/article/0a47a377e6874c068b20f32b50811c52
Autor:
Alejandra Martínez-Pérez, Rocío Granda-Díaz, Candelaria Aguilar-García, Christian Sordo-Bahamonde, Segundo Gonzalez
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-13 (2024)
Abstract Treatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting
Externí odkaz:
https://doaj.org/article/1fed91f0667c4c73bc5f911cab476644
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-21 (2024)
Abstract Ovarian cancer, often referred to as the “silent killer,” is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to i
Externí odkaz:
https://doaj.org/article/27ce0c22a5cb4ddc8eb5304d7b6146e5
Autor:
Su Yin Lim, Ines Pires da Silva, Nurudeen A. Adegoke, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Jenny H. Lee, Helen Rizos
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-6 (2024)
Abstract Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, providing significant benefit to patients across various tumour types, including melanoma. However, around 40% of melanoma patients do not benefit from ICI treatment, and
Externí odkaz:
https://doaj.org/article/cb455c8e98424ccdb0dd49216c915acf
Autor:
Huancheng Zeng, Qiongzhi Jiang, Rendong Zhang, Zhemin Zhuang, Jundong Wu, Yaochen Li, Yutong Fang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Melanoma is a highly malignant form of skin cancer that typically originates from abnormal melanocytes. Despite significant advances in treating metastatic melanoma with immune checkpoint blockade (ICB) therapy, a substantial number of patie
Externí odkaz:
https://doaj.org/article/3268511e6b454ac498635f5378e8d0d4
Autor:
Xiaodian Zhang, Hailong Tian, Yang Chen, Baichuan Liang, Edouard C. Nice, Canhua Huang, Na Xie, Shaojiang Zheng
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-20 (2024)
Abstract Immunotherapy has shown marked progress in promoting systemic anti-colorectal cancer (CRC) clinical effects. For further effectively sensitizing CRC to immunotherapy, we have engineered a pH-sensitive zeolitic imidazolate framework-8 (CS/NPs
Externí odkaz:
https://doaj.org/article/c680ef09da4d46f4a74a0ba001838a51
Autor:
Bowen Zeng, Lina Pian, Yanhong Liu, Shuangqing Wang, Nuoya Wang, Chao Liu, Hao Wu, Hongshuang Wan, Liqing Chen, Wei Huang, Zhonggao Gao, Xuezhe Yin, Mingji Jin
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Breast cancer therapy has significantly advanced by targeting the programmed cell death-ligand 1/programmed cell death-1 (PD-L1/PD-1) pathway. BMS-202 (a smallmolecule PD-L1 inhibitor) induces PD-L1 dimerization to block PD-1/PD-L1 interacti
Externí odkaz:
https://doaj.org/article/51f62b1377604f8bb41e12e6d76353bc
Autor:
Xiaokun Zhang, Ye Wu, Jiayi Lin, Shengxin Lu, Xinchen Lu, Aoyu Cheng, Hongzhuan Chen, Weidong Zhang, Xin Luan
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 9, Pp 3818-3833 (2024)
Immunotherapies hold immense potential for achieving durable potency and long-term survival opportunities in cancer therapy. As vital biological mediators, peptides with high tissue penetration and superior selectivity offer significant promise for e
Externí odkaz:
https://doaj.org/article/4e96d6cb0559410681783ee1a600fbe2
Autor:
Meiling Fu, Jinxin Li, Zuodong Xuan, Zeyuan Zheng, Yankuo Liu, Zeyi Zhang, Jianzhong Zheng, Min Zhong, Bin Liu, Yifan Du, Lei Zhang, Huimin Sun
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Prostate cancer (PCa) is one of the most common male genitourinary system malignancies. Despite the significant benefits of anti-PD-L1 immune checkpoint inhibitor therapy in other cancers, the reasons for its poor therapeutic efficacy in pro
Externí odkaz:
https://doaj.org/article/db173f947e174d30beaeb154fbeb271f